Beta-Agonist Lung injury Trial-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
To evaluate whether or not, in patients with ARDS, an i.v. infusion of salbutamol given at 15 g/kg ideal body weight (IBW)/hour for up to 7 days, compared with a placebo (0.9% sodium chloride) infusion, reduces 28-day all-cause mortality and other clinical outcomes. To evaluate salbutamol's clinical effectiveness and its cost-effectiveness in subgroups of patients.

Authors' conclusions
Treatment with i.v. salbutamol early in the course of ARDS was poorly tolerated, is unlikely to be beneficial and could worsen outcomes. Further trials of -agonists in patients with ARDS are unlikely to be conducted. Some questions remain, such as whether or not there may be benefit at a different dose or in specific populations, but any studies investigating these would require a very strong rationale.

Final publication URL
http://www.journalslibrary.nihr.ac.uk/hta/hta17380/#/abstract

Link to NHS EED abstract
http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?AccessionNumber=22013052632& UserID=0

Additional data URL
http://www.journalslibrary.nihr.ac.uk/hta/volume-17/issue-38

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Respiratory Distress Syndrome, Adult; Adrenergic beta-2 Receptor Agonists; Albuterol; Cost-Benefit Analysis; Lung Injury

Language Published
English

Country of organisation
England

English summary
An English language summary is available.